Additional Investment in Numab Therapeutics

RTW Biotech Opportunities Ltd

14 January 2025

 

LEI: 549300Q7EXQQH6KF7Z84

14 January 2025

RTW Biotech Opportunities Ltd

Additional Investment in Numab Therapeutics

RTW Biotech Opportunities Ltd (the "Company"), a London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note an additional investment in the Series C extension of Numab Therapeutics ("Numab"), a Swiss clinical stage biotech advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology. 

Numab announced the completion of its CHF 50 million (~US$55m) Series C extension, in which the Company participated alongside other investment vehicles managed by RTW Investments, LP (the "Investment Manager"). The extension brought total Series C funding to CHF 180 million (~US$196m). The funds will be used to support the advancement of multiple potentially first-in-class and best-in-class programs into clinical development. The Company first invested in Numab's original Series C round in May of 2021.

Roderick Wong, Managing Partner and CIO at the Investment Manager said, "We are delighted to continue supporting Numab Therapeutics. Their innovative approach to developing multi-specific antibodies is particularly promising, and we believe that their groundbreaking research and development efforts hold great potential for transforming autoimmune and cancer treatments. Following J&J's announcement last summer to acquire Numab subsidiary, Yellow Jersey Therapeutics, we are optimistic that our continued partnership and this latest financing round will contribute to other significant advancements in immunology and oncology therapeutics."

The full text of the announcement can be accessed at https://www.numab.com.

  For Further Information

RTW Investments, LP	[phone]
Woody Stileman, Managing Director, Business Development Krisha McCune, Director, Investor Relations	[e-mail]
Cadarn Capital (PR & Communications/Distribution & IR Partner)	[phone]
Lucy Clark (PR)	[e-mail]
David Harris (Distribution)	[phone] [e-mail]
Deutsche Numis (Joint Corporate Broker) Freddie Barnfield	[phone]
Nathan Brown
Euan Brown
BofA Securities (Joint Corporate Broker)	[phone]
Edward Peel
Alex Penney
Elysium Fund Management Limited Joanna Duquemin Nicolle, Chief Executive Officer Sadie Morrison, Managing Director	[phone]
Morgan Stanley Fund Services USA LLC	[phone]

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.

***********

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

**********

 

END